⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NSRX News
Nasus Pharma Ltd.
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
globenewswire.com
NSRX
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
globenewswire.com
JUNS
DYAI
PHIO
CVKD
TNXP
MTVA
XAIR
AEMD
NSRX
ICU
JAGX
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
globenewswire.com
NSRX
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
globenewswire.com
NSRX
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
globenewswire.com
NSRX
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
globenewswire.com
NSRX
Nasus Pharma to Participate in Upcoming Investor Conferences
globenewswire.com
NSRX
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
globenewswire.com
NSRX
Nasus Pharma Announces Closing of $15.0 Million Private Placement
globenewswire.com
NSRX
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
globenewswire.com
NSRX